Stay up to date on PsychoGenics and the world of preclinical drug discovery. Filter by Year All Years 2023 2022 2021 2020 Clear Search Clear PsychoGenics Announces Exclusive Global License for an IND-ready ENT1 Inhibitor for the Treatment of Neuropsychiatric DisordersDecember 1, 2023 PsychoGenics Launches Updated Corporate Identity and BrandNovember 10, 2023 This company is using AI to develop drugs. Schizophrenia is its first targetAugust 4, 2023 World Wellbeing Week 2023: Celebrating drug discovery innovationJune 29, 2023 How AI Will Make Our Lives Better (And Worse)May 31, 2023 AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’May 10, 2023 PsychoGenics’ SmartCube prompts a reevaluation of CNS drug discoveryMay 8, 2023 PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug DiscoveryApril 6, 2023 5 Women Leading the Way in BiotechMarch 8, 2023 PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease DayFebruary 28, 2023 The next generation of antidepressants and antipsychoticsFebruary 24, 2023 2023 Pharma PredictionsFebruary 9, 2023 {{ x.title }}{{ x.date }} Load More There are no articles to display.